Skip to content
value.today
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is listed today as Neumora Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Neumora Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$474 MIssued in a merger or acquisition$250 million to $1 billion

Neumora Therapeutics, Inc.: Private sale, Sep 2020

Investors in this round

124 investors had bought by the notice of Jan 3, 2023: 124 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 16 investors are named for Neumora Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$474 M of $474 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joshua Pinto · Executive Officer
  • Paul Berns · Executive Officer, Director
  • Tamara Tompkins · Executive Officer
  • Alaa Halawa · Director
  • Kari Stefansson · Director
  • Kristina Burow · Director
  • Matthew Fust · Director
  • Maykin Ho · Director
  • Robert Nelsen · Director
  • Stacie Weninger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tamara Tompkins, Chief Legal Officer and Secretary. Source: SEC Form D, newest notice filed Jan 3, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neumora Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2023).

    SEC Form D · Jan 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2023

That is all the official record says: Neumora Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Neumora Therapeutics, Inc. are on record.

Investors#

16 named in official filings. Open an investor to see everything it has backed.

Investors in Neumora Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Amgen IncCompanynot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Fund VIII Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Arch Venture Fund VII LPVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Fund XII, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Fund X, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Fund X Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners VIII, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners VII, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners VII, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners XII, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners XII, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners X, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
ARCH Venture Partners X Overage, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Kristina BurowPersonnot statednot statedHeld Series A-1 preferred stock, 10% owner, director (Form 3, 2023)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Neumora Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neumora Therapeutics, Inc.
NameRoleNamed in
Joshua PintoExecutive officerJan 2023
Paul BernsExecutive officerJan 2023
Tamara TompkinsExecutive officerJan 2023
Alaa HalawaDirectorJan 2023
Kari StefanssonDirectorJan 2023
Kristina BurowDirectorJan 2023
Matthew FustDirectorJan 2023
Maykin HoDirectorJan 2023
Paul BernsDirectorJan 2023
Robert NelsenDirectorJan 2023
Stacie WeningerDirectorJan 2023

Went public since 2023. Its SEC number is that of a company listed on a stock exchange.